Effect of sCD40L Combined with Vinorelbine on Lung Adenocarcinoma Cell A549

Background and objective The results of published data on the effect of CD40 signal related to cancer cell sensitivity to chemotherapy are inconclusive. The aim of this study is to investigate the effect of soluble CD40 ligand (sCD40L) combined with vinorelbine on lung adenocarcinoma cell line A549....

Full description

Bibliographic Details
Main Authors: Shan LIU, Bo CHEN, Yan LI, Weihong ZHAO, Jianqing WU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2010-07-01
Series:Chinese Journal of Lung Cancer
Subjects:
Online Access:http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2010.07.06&path[]=1603
Description
Summary:Background and objective The results of published data on the effect of CD40 signal related to cancer cell sensitivity to chemotherapy are inconclusive. The aim of this study is to investigate the effect of soluble CD40 ligand (sCD40L) combined with vinorelbine on lung adenocarcinoma cell line A549. Methods Lung adenocarcinoma A549 cells were chosen as target cells and CD40 signal was stimulated by sCD40L. MTT assay and flow cytometry were used to determine the changes of cell proliferation, cell cycle and apoptosis of A549 cells treated by vinorelbine after CD40 was stimulated. The activity of Caspase-3 was measured using Caspase-3 cellular activity assay kit plus. Results After CD40 stimulation, an increase of inhibition on CD40 positive cell line A549 proliferation was confirmed when vinorelbine was added (P < 0.05). However, no significant changes were shown in apoptosis and cell cycle (P>0.05). On the other hand, the activity of Caspase-3 was substantially decreased (P < 0.05). Conclusion Stimulation of CD40 can increase lung adenocarcinoma cell line A549 sensitivity to vinorelbine, which may be through a non-apoptosis, Caspase independent mechanism, and not associated with the inhibition of cell cycle.
ISSN:1009-3419
1999-6187